Beneficial role of simvastatin in experimental autoimmune myositis.

CONCLUSION: Simvastatin at 20 mg/kg decreases the severity of myositis in experimental autoimmune myositis and is a candidate of being a disease-modifying agent in inflammatory myopathies. PMID: 31863923 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31863923?dopt=Abstract

Source: International Immunopharmacology - December 17, 2019 Category: Allergy & Immunology Authors: Maalouly G, Hajal J, Saliba Y, Rached G, Layoun H, Smayra V, Sleilaty G, Irani C, Fares N Tags: Int Immunopharmacol Source Type: research